Advertisement

Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases

  • Qichen Chen
  • Chaorui Wu
  • Hong Zhao
  • Jianxiong Wu
  • Jianjun Zhao
  • Xinyu Bi
  • Zhiyu Li
  • Zhen Huang
  • Yefan Zhang
  • Jianguo ZhouEmail author
  • Jianqiang Cai
Original Article
  • 29 Downloads

Abstract

Background

Neutropenia, the major adverse event in chemotherapy, is associated with favourable clinical outcome in several solid tumours. We aimed to investigate the predictive value of neo-adjuvant chemotherapy (NAC)–induced neutropenia for the pathological response and prognosis in colorectal liver metastases (CRLM) patients.

Methods

A retrospective review was performed in 141 CRLM patients receiving NAC followed by liver resection. A logistic regression was applied to analyse potential predictors. A Cox proportional hazards analysis was used to analyse survival.

Results

Neutropenia due to NAC was observed in 42.6% (60/141) of all patients, and grade 3/4 neutropenia was noted in 31.7% (19/60). A pathological response (tumour regression grade (TRG) 1–3) was reported in 46.1% (65/141) of patients. Multivariate analysis showed that neutropenia significantly predicted the favourable pathological response (OR = 3.718, 95% CI 1.716–8.329, P = 0.001), as well as targeted therapy, good differentiation and preoperative CEA < 10 ng/ml as independent predictors of favourable histological response. Of the patients, 54.6% (77/141) had postoperative complications, including 28 major complications (28/77, 36.4%). Severe neutropenia significantly predicted postoperative major complications in multivariate analysis (OR = 4.077, 95% CI 1.184–14.038, P = 0.026). Compared to patients without neutropenia, patients with neutropenia had significantly better progression-free survival (PFS) (P = 0.007; mPFS, 10.2 months vs. 6.7 months). Patients with histological response had significantly better PFS than patients with no histological response (P = 0.001; mPFS, 10.0 months vs. 5.5 months). According to multivariate analyses, neutropenia was a significant predictor for better PFS (HR = 0.613, 95% CI 0.406–0.925, P = 0.020) but not OS.

Conclusions

For CRLM patients receiving NAC followed by liver resection, NAC-induced neutropenia was a significant predictor of favourable pathological response, postoperative major complications and better prognosis, which makes it useful for CRLM patients in guiding treatment approaches and prognosis assessments.

Keywords

Colorectal cancer liver metastasis Liver resection Neo-adjuvant chemotherapy Neutropenia Histological response Prognosis 

Notes

Acknowledgments

We are grateful to Dr. Xingjin Wu for critically reading the manuscript and for her valuable comments.

Author Contribution

All authors have made substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising, and final approval of the version to be published.

Compliance with Ethical Standards

Conflicts of Interest

All authors have no conflicts of interests to disclose.

Ethical Approval

This study was approved by the Institutional Review Board of the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. All patients provided written informed consent.

References

Author names in bold designate shared co-first authorship

  1. 1.
    Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery. 2009;22(4):191–7.  https://doi.org/10.1055/s-0029-1242458.Google Scholar
  2. 2.
    Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. European journal of cancer (Oxford, England : 1990). 2006;42(14):2212–21.  https://doi.org/10.1016/j.ejca.2006.04.012.Google Scholar
  3. 3.
    Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Annals of surgery. 2008;247(1):125–35.  https://doi.org/10.1097/SLA.0b013e31815aa2c2.Google Scholar
  4. 4.
    van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. The British journal of surgery. 2010;97(3):383–90.  https://doi.org/10.1002/bjs.6947.Google Scholar
  5. 5.
    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(9):2038–48.  https://doi.org/10.1200/jco.2005.00.349.Google Scholar
  6. 6.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet (London,England).2008;371(9617):1007–16. https://doi.org/10.1016/s0140-6736(08)60455-9.Google Scholar
  7. 7.
    Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quenet F, Portier G, Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer chemotherapy and pharmacology. 2008;62(2):195–201.  https://doi.org/10.1007/s00280-007-0588-3.Google Scholar
  8. 8.
    Blazer DG, 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(33):5344–51.  https://doi.org/10.1200/jco.2008.17.5299.Google Scholar
  9. 9.
    Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology. 2010;17(11):2870–6.  https://doi.org/10.1245/s10434-010-1166-1.Google Scholar
  10. 10.
    Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. British journal of cancer. 2015;113(9):1298–304.  https://doi.org/10.1038/bjc.2015.321.Google Scholar
  11. 11.
    Pang TC, Spiro C, Ramacciotti T, Choi J, Drummond M, Sweeney E, Samra JS, Hugh TJ. Complications following liver resection for colorectal metastases do not impact on long-term outcome. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2015;17(2):185–93.  https://doi.org/10.1111/hpb.12327.Google Scholar
  12. 12.
    Tranchart H, Gaillard M, Chirica M, Ferretti S, Perlemuter G, Naveau S, Dagher I. Multivariate analysis of risk factors for postoperative complications after laparoscopic liver resection. Surgical endoscopy. 2015;29(9):2538–44.  https://doi.org/10.1007/s00464-014-3965-0.Google Scholar
  13. 13.
    D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Annals of surgical oncology. 2011;18(4):1096–103.  https://doi.org/10.1245/s10434-010-1409-1.Google Scholar
  14. 14.
    Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology. 2005;6(9):669–77.  https://doi.org/10.1016/s1470-2045(05)70255-2.Google Scholar
  15. 15.
    Sunaga T, Suzuki S, Kogo M, Kurihara T, Kaji S, Koike N, Harada N, Suzuki M, Kiuchi Y. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. European journal of cancer care. 2014;23(3):394–400.  https://doi.org/10.1111/ecc.12120.Google Scholar
  16. 16.
    Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC cancer. 2016;16:467.  https://doi.org/10.1186/s12885-016-2491-y.Google Scholar
  17. 17.
    Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British journal of cancer. 2007;97(1):37–42.  https://doi.org/10.1038/sj.bjc.6603831.Google Scholar
  18. 18.
    Han Y, Yu Z, Wen S, Zhang B, Cao X, Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast cancer research and treatment. 2012;131(2):483–90.  https://doi.org/10.1007/s10549-011-1799-1.Google Scholar
  19. 19.
    Kim YH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer. Journal of gynecologic oncology. 2009;20(3):146–50.  https://doi.org/10.3802/jgo.2009.20.3.146.Google Scholar
  20. 20.
    Su Z, Mao YP, OuYang PY, Tang J, Lan XW, Xie FY. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC cancer. 2015;15:429.  https://doi.org/10.1186/s12885-015-1442-3.Google Scholar
  21. 21.
    Han HS, Rybicki LA, Thiel K, Kalaycio ME, Sobecks R, Advani A, Brown S, Sekeres MA. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leukemia & lymphoma. 2007;48(8):1561–8.  https://doi.org/10.1080/10428190701474373.Google Scholar
  22. 22.
    Shiozawa Y, Takita J, Kato M, Sotomatsu M, Koh K, Ida K, Hayashi Y. Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia. Oncol Lett. 2014;7(4):1169–74.  https://doi.org/10.3892/ol.2014.1822.Google Scholar
  23. 23.
    Robb WB, Messager M, Goere D, Pichot-Delahaye V, Lefevre JH, Louis D, Guiramand J, Kraft K, Mariette C. Predictive factors of postoperative mortality after junctional and gastric adenocarcinoma resection. JAMA surgery. 2013;148(7):624–31.  https://doi.org/10.1001/jamasurg.2013.63.Google Scholar
  24. 24.
    Robb WB, Messager M, Gronnier C, Tessier W, Hec F, Piessen G, Mariette C. High-grade toxicity to neoadjuvant treatment for upper gastrointestinal carcinomas: what is the impact on perioperative and oncologic outcomes? Annals of surgical oncology. 2015;22(11):3632–9.  https://doi.org/10.1245/s10434-015-4423-5.Google Scholar
  25. 25.
    Kanat O. Current treatment options for patients with initially unresectable isolated colorectal liver metastases. World journal of clinical oncology. 2016;7(1):9–14.  https://doi.org/10.5306/wjco.v7.i1.9.Google Scholar
  26. 26.
    Passot G, Soubrane O, Giuliante F, Zimmitti G, Goere D, Yamashita S, Vauthey JN. Recent advances in chemotherapy and surgery for colorectal liver metastases. Liver cancer. 2016;6(1):72–9.  https://doi.org/10.1159/000449349.Google Scholar
  27. 27.
    Institute NC. Common terminology criteria for adverse events (CTCAE), version 4.0. 2010. http://evs.nci.nih.gov/%0Aftp1/CTCAE/CTCAE_ 4.03_2010-06-14_QuickReference_5x7.pdf.
  28. 28.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 2009;45(2):228–47.  https://doi.org/10.1016/j.ejca.2008.10.026.Google Scholar
  29. 29.
    Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of oncology : official journal of the European Society for Medical Oncology. 2007;18(2):299–304.  https://doi.org/10.1093/annonc/mdl386.Google Scholar
  30. 30.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of surgery. 2004;240(2):205–13.Google Scholar
  31. 31.
    Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, Olsen M, Schildt S, Sweet E, Wenner CA, Martzen MR. Immune defects in breast cancer patients after radiotherapy. Journal of the Society for Integrative Oncology. 2008;6(3):110–21.Google Scholar
  32. 32.
    Ohrmalm L, Smedman C, Wong M, Broliden K, Tolfvenstam T, Norbeck O. Decreased functional T lymphocyte-mediated cytokine responses in patients with chemotherapy-induced neutropenia. Journal of internal medicine. 2013;274(4):363–70.  https://doi.org/10.1111/joim.12100.Google Scholar
  33. 33.
    Konishi H, Fujiwara H, Shiozaki A, Hiramoto H, Kosuga T, Komatsu S, Ichikawa D, Okamoto K, Otsuji E. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. International journal of clinical oncology. 2016;21(1):95–101.  https://doi.org/10.1007/s10147-015-0875-7.Google Scholar
  34. 34.
    Sabanathan D, Eslick GD, Shannon J. Use of neoadjuvant chemotherapy plus molecular targeted therapy in colorectal liver metastases: a systematic review and meta-analysis. Clinical colorectal cancer. 2016;15(4):e141-e7.  https://doi.org/10.1016/j.clcc.2016.03.007.Google Scholar
  35. 35.
    Okuno M, Hatano E, Nishino H, Seo S, Taura K, Uemoto S. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases? A systematic review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017;43(6):1003–12.  https://doi.org/10.1016/j.ejso.2016.08.019.Google Scholar
  36. 36.
    Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015;41(7):868–74.  https://doi.org/10.1016/j.ejso.2015.03.223.Google Scholar
  37. 37.
    Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(1):320–9.  https://doi.org/10.1158/1078-0432.ccr-09-1555. Google Scholar
  38. 38.
    Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutrition and cancer. 2014;66(4):583–9.  https://doi.org/10.1080/01635581.2014.894103.Google Scholar
  39. 39.
    van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. The British journal of surgery. 2012;99(4):550–7.  https://doi.org/10.1002/bjs.7823.Google Scholar
  40. 40.
    Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. European journal of cancer (Oxford, England : 1990). 2016;57:58–67.  https://doi.org/10.1016/j.ejca.2015.12.030.Google Scholar
  41. 41.
    Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, Svendsen LB, Christensen JF. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Annals of surgery. 2018;268(1):58–69.  https://doi.org/10.1097/sla.0000000000002679.Google Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  • Qichen Chen
    • 1
  • Chaorui Wu
    • 2
  • Hong Zhao
    • 1
  • Jianxiong Wu
    • 1
  • Jianjun Zhao
    • 1
  • Xinyu Bi
    • 1
  • Zhiyu Li
    • 1
  • Zhen Huang
    • 1
  • Yefan Zhang
    • 1
  • Jianguo Zhou
    • 1
    Email author
  • Jianqiang Cai
    • 1
  1. 1.Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations